High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation

Diabetes Care. 2005 Mar;28(3):758-9. doi: 10.2337/diacare.28.3.758.
No abstract available

Publication types

  • Case Reports
  • Comparative Study
  • Letter

MeSH terms

  • Amino Acid Substitution*
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diarrhea / chemically induced*
  • Female
  • Glyburide / adverse effects
  • Glyburide / therapeutic use*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Infant
  • Insulin / therapeutic use*
  • Mutation, Missense
  • Potassium Channels, Inwardly Rectifying / genetics*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Kir6.2 channel
  • Potassium Channels, Inwardly Rectifying
  • Glyburide